f This study was undertaken to examine the performance of the Fungitell ␤-glucan (BG) assay, to compare it with that of the galactomannan (GM) test for the diagnosis of invasive aspergillosis (IA) in patients with hematological malignancies, and to examine the rates of false-positive BG and GM test results due to ␤-lactam antibiotics among sera of patients with Gram-positive or Gram-negative bacteremia and selected sera with false-positive results from the GM test. Serum samples from 105 patients with proven (n ‫؍‬ 14) or probable (n ‫؍‬ 91) IA, 97 hematology patients at risk for invasive fungal infections, 50 healthy blood donors, and 60 patients with bacteremia were used to study the sensitivities and specificities of the assays. The GM test was more specific than the BG assay (97% versus 82%, respectively; P ‫؍‬ 0.0001) and the BG assay was more sensitive than the GM test (81% versus 49%, respectively; P < 0.0001) for IA diagnosis. The study of 49 separate batches of ␤-lactam antibiotics showed high and very similar rates of false-positive results for the GM and BG assays (29 and 33%, respectively; P ‫؍‬ 0.82) but with an almost complete lack of concordance between the 2 assays. For patients with bacteremia, the rate of false-positive results was much higher with the BG test than with the GM test (37% versus 2%, respectively; P < 0.0001), with no significant difference between Gram-positive and Gram-negative bacteremia. In conclusion, the BG test may be useful for the diagnosis of IA because of its high sensitivity in comparison with the GM test, but the overall benefit of this assay remains limited because of its inadequate specificity and its cost.
I
nvasive aspergillosis (IA) remains a significant cause of morbidity and mortality in immunocompromised patients. Despite the availability of new antifungal drugs, the mortality rate for IA remains high, partly due to the difficulty and delay of diagnosis based on clinical, radiological, and mycological methods (1) . Because culture-based diagnostic methods have limited performance, non-culture-based methods are increasingly being used. Detection of circulating galactomannan (GM) with a sandwich enzyme-linked immunosorbent assay (ELISA) (Platelia Aspergillus; Bio-Rad, Marnes-la-Coquette, France) has been widely used (2, 3) . Although the Platelia Aspergillus assay has become an important tool for the diagnosis of IA, false-positive (4-6) and falsenegative (3, 7) results with this test have been reported. The occurrence of false-positive and false-negative results with the Platelia Aspergillus assay is a major drawback of this technique, as such results may lead to unjustified invasive or costly investigations or antifungal therapy in cases of false-positive results and underdiagnosis or delayed diagnosis in cases of false-negative results.
Another serum marker for the presence of invasive fungal infections (IFIs) is (1-3)-␤-D-glucan (BG), which has been included in the relevant European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group (MSG) diagnostic criteria (8) . BG is a component of the cell walls of most fungi. The main exceptions are Mucorales and cryptococci, which release no or little BG to be detected in human serum (9) . The measurement of BG levels is based on the Limulus test (10) . BG activates factor G, a serine protease zymogen of Limulus amebocyte lysates, which are extracted from amebocytes of horseshoe crab species. This in turn activates a coagulation cascade. The activity of this reaction can be measured with the use of colorimetric or turbidimetric methods. The Fungitell assay (Associates of Cape Cod, Inc.) is a chromogenic kinetic test that was approved by the Food and Drug Administration in 2003 and carries the European CE label for the presumptive diagnosis of IFIs. However, the major limitations of BG testing for routine use are false-positive reactions (11-16) with interfering substances (17) .
The main purpose of this study was to assess the utility of the Fungitell BG assay for the diagnosis of IA. This involved (i) a study of the performance of the BG test, (ii) a comparison of the performance of the BG and GM tests, and (iii) a study of the rates of false-positive BG and GM test results due to antibiotics and in sera of patients with Gram-positive and Gram-negative bacterial infections.
MATERIALS AND METHODS

Patients.
Sera from 312 patients and control subjects were studied and allocated into four separate groups. The first group comprised 105 patients with hematological malignancies with proven (n ϭ 14) or probable (n ϭ 91) IA, according to EORTC/MSG diagnostic criteria with the exclusion of BG testing (8) ; this group was used to analyze the performance of the BG test. Within this group, a subset of 69 patients (the second group) whose laboratory diagnosis of IA was based on direct tests only (positive cytological, direct microscopic, and/or culture results) was selected; this subset was used to compare the BG and GM tests. The underlying diseases of the patients in these two first groups and whether they had received an allogeneic stem cell transplant are reported in Table 1 .
A control group (the third group) comprised 97 consecutive patients from hematology wards who were at risk for an IFI but without any symptoms of an IFI, were routinely screened for the presence of GM, and did not develop any sign of an IFI during the follow-up period and 50 healthy blood donors from a local transfusion center. The fourth group comprised 60 patients with positive blood culture results for either Grampositive or Gram-negative bacteria.
For each patient, one blood sample was studied, either selected randomly from among those collected on a routine basis (for hematology patients without an IFI) or collected close to the time of diagnosis (for patients with IA or bacteremia). In addition, 48 sera that yielded unexplained false-positive GM test results, which had been selected over 5 years of routine practice, were analyzed for BG.
Antibiotics. A total of 49 separate batches of ␤-lactam antibiotics were tested, including 33 batches of piperacillin-tazobactam (Wyeth, Mylan, France) (1 g/vial), 9 of amoxicillin (GlaxoSmithKline, France) (1 g/vial), and 7 of amoxicillin-clavulanic acid (GlaxoSmithKline, France) (1 g/vial). The vials were reconstituted at the concentrations used for intravenous administration, according to the manufacturers' instructions, and were tested. For each batch, an aliquot was processed by the same procedure as that applied to serum. Batches that yielded GM indices of Ͼ0.5 or BG levels of Ͼ80 pg/ml when undiluted were retested, to estimate the true level of GM or BG and to avoid a prozone effect in the GM test, as observed previously with antibiotics (5). Dilutions were prepared in sterile 0.9% NaCl (for GM) or pyrogen-free water (for BG) and then were tested for GM and BG.
Antigen detection techniques. Blood samples were collected in sterile BG-free vacuum tubes. Serum was separated, divided into aliquots, and stored in BG-free tubes at 2°C to 8°C for up to 48 h or frozen at Ϫ20°C until testing.
GM antigen was detected using a sandwich immunocapture ELISA (Platelia Aspergillus; Bio-Rad, Marnes-la-Coquette, France), according to the manufacturer's recommendations. Positive and negative controls were included in each assay. A result was considered positive with index values of Ն0.5 in duplicate tests. BG was detected with the Fungitell test kit, essentially as recommended by the manufacturer (Associates of Cape Cod). Briefly, serum samples were treated for 10 min at 37°C with a solution containing 0.6 M KCl and 0.125 M KOH. A kinetic colorimetric assay was performed at 37°C and monitored at 405 nm for 25 min. The concentration of BG in each sample was automatically calculated using a calibration curve prepared with standard solutions ranging from 6.23 to 100 pg/ml. BG levels of Ն80 pg/ml were considered positive results. Serum assays were performed in duplicate. BG tests were performed without knowledge of the results of GM determinations.
Statistical analysis. The diagnostic performance of the GM and BG tests was evaluated as sensitivity and specificity, with 95% confidence intervals (CIs). Additionally, positive and negative likelihood ratios (LRs) were computed for the GM and BG tests separately and for the combination of the two. Briefly, the positive LR is the true-positive rate divided by the false-positive rate, and the negative LR is the false-negative rate divided by the true-negative rate. The LR summarizes how much more likely patients with IA are to have that particular result (positive or negative for a binary result, or a given result for a multiple-value test) than are patients without IA (controls) (18) . It is generally considered that LRs of Ͼ10 or Ͻ0.1 have large effects on diagnosis and LRs of 5 to 10 or 0.1 to 0.2 have moderate effects. The impact on diagnosis is considered small for LRs of 2 to 5 or 0.2 to 0.5 and negligible for LRs of 0.5 to 2, with a LR of 1 indicating no diagnostic accuracy at all (19) . Test results in the same group of patients were compared using McNemar's test for paired proportions. Between-group comparisons were performed with Fisher's exact tests or Wilcoxon rank-sum tests. Agreement between tests was assessed using the kappa statistic, and the overall diagnostic performance was summarized by Youden's index, defined as sensitivity ϩ specificity Ϫ 1.
RESULTS
In a first analysis, data obtained for 105 subjects with IA and 147 controls (50 donors at a local transfusion center and 97 subjects from hematology wards) were analyzed for determination of BG test performance. The sensitivity and specificity were 78% and 82%, respectively. Likelihood ratios of 4.25 for a positive result and 0.27 for a negative result suggested weak effects on diagnosis for both positive and negative results.
In a second analysis, the performance characteristics of BG and GM tests were compared using the subset of 69 patients with IA whose laboratory diagnoses were established independently of the results of GM or BG tests (if performed). For BG testing, restricting the analysis to those patients yielded results close to those of the first analysis, i.e., sensitivity of 81%, positive LR of 4.42, and negative LR of 0.23; the specificity was unchanged since the definition of control was unchanged.
The distributions of GM index values and BG levels according to the type of IA diagnosis are presented in Fig. 1 , and the diagnostic performance characteristics of the two tests are presented in Table 2 . The GM assay was found to be more specific than the BG assay (97% versus 82%, respectively; P ϭ 0.0001) and the BG assay more sensitive than the GM assay (81% versus 49%, respectively; P ϭ 0.0003) for IA diagnosis. Overall, based on Youden's index (P ϭ 0.020), the BG assay was found to perform better than the GM assay.
Analysis of likelihood ratios (LRs) showed a better diagnostic value for a positive GM test result (positive LR, Ͼ10 [lower 95% confidence limit, Ͼ5]) than for a positive BG test result. Symmetrically, a negative BG assay result had a better diagnostic value Table 3 . Positive results were observed in 22/60 cases with the BG assay, compared with 1/60 cases with the GM assay (P Ͻ 0.0001). No significant difference was found in the positive BG test result rates for the Gram-negative and Gram-positive groups (P ϭ 0.55) or between BG levels in these two groups (P ϭ 0.23). The 7 Gram-negative bacteria implicated in false-positive BG test results were Escherichia coli (n ϭ 2), Enterobacter faecalis (n ϭ 1), Acinetobacter baumannii (n ϭ 1), Klebsiella pneumoniae (n ϭ 1), Providencia alcalifaciens (n ϭ 1), and Pseudomonas aeruginosa (n ϭ 1). The 15 Gram-positive bacteria found in cases of false-positive BG test results were Staphylococcus aureus (n ϭ 12), Peptostreptococcus magnus (n ϭ 1), and a Micrococcus sp. (n ϭ 1).
The analysis of GM and BG test results for antibiotic samples is presented in Table 4 . Similar rates of false-positive results were observed for the two assays (GM test, 29%; BG test, 33%; P ϭ 0.82) but there was no agreement between the two assays (kappa ϭ 0.04), with only 5 samples being positive by both tests and 20 being positive by one or the other. Testing of the panel of 48 sera with false-positive results from the GM test showed that 33 sera were BG test negative (68.5%) and 15 were BG test positive.
DISCUSSION
The diagnostic performance of the (1-3)-␤-D-glucan assay for invasive fungal infections has been evaluated in several meta-analyses (20) (21) (22) , and this assay is considered a useful diagnostic tool if it is used for diagnosis among immunocompromised patients, with knowledge of the limitations of the assay (17) . For the diagnosis of invasive aspergillosis, BG and GM assays seem to be in the same performance range, considering the wide dispersion of the reported sensitivity and specificity values in studies. The reported sensitivity values for the GM assay have been variable, with a range of 30 to 100%, and specificity values have ranged from 38% to 98% (23, 24) . Similarly, variable results have been reported for the BG assay, with sensitivity values ranging from 80% to 90% and specificity values ranging from 36% to 92%, according to the cutoff value used (25, 26) . However, few studies have performed direct comparisons of the 2 assays for the diagnosis of IA in the same patients. One study favored the BG assay (27) , one study favored the GM assay (28), one found no major difference between the two assays (29) , and two showed moderate agreement between them (30, 31) . Therefore, we undertook this study to examine the performance of the BG assay for the diagnosis of invasive aspergillosis in patients with hematological malignancies.
Encouraging results were observed for the diagnosis of IA, since the BG test was found to be more sensitive than the GM test for patients with proven or probable IA, but this higher sensitivity was associated with lower specificity versus the GM test. To estimate the benefits of BG and/or GM tests for routine practice, we paid particular attention to characterizing the risk of false-positive results. Several factors that may increase BG levels for reasons other than IFIs have been identified (9), including hemodialysis with cellulose membranes (13) , thrombocyte infusion with leukocyte-removing filters (16, 32) , the administration of human blood products (immunoglobulins or albumins) (33, 34) , the use of antibiotics such as amoxicillin-clavulanate or piperacillin-tazobactam (14, 27) , the presence of serious bacterial infections (35) , the use of surgical gauzes containing glucan (36) , and severe mucositis (37) . Among these, we focused on ␤-lactams, which also cause false-positive GM test results, and bacteremia, as a possible confounding cause of fever in hematology patients. Regarding the interacting effects of ␤-lactams, our results showed high and similar rates of false-positive results with the 2 assays but with an almost complete lack of concordance between the two tests, meaning that the tests were sensitive to different specific interacting factors. It was suggested previously that the release of galactomannan during the manufacturing process for some antibiotics might be responsible for positive GM assay results (38) . The same explanation can be proposed for the BG assay, since (1-3)-␤-Dglucan is present in some supports, such as cellulose filters, that can be used during manufacturing (16) . For patients with bacteremia, our results showed that the rate of false-positive results was much higher for the BG assay than for the GM assay (P Ͻ 0.0001), i.e., 30% false-positive BG test results in bacteremic patients, with no significant difference between Gram-positive and Gram-negative bacteremia. The interacting effects of bacteremia on the performance of BG assays are still debated. False-positive BG test results during bacteremia were not found in a recent prospective study (39) but were reported, at a rate similar to that in our study, for patients with positive blood culture results for Gram-positive bacteria (35) . We have no explanations for these discrepant results. Based on the individual performance of each test and their discordances, the use of the two tests to complement each other can be proposed. As in another study (29) , we found that combining the two tests had some benefit in terms of specificity, since the association of positive BG assay results and positive GM assay results was almost 100% specific, but with lower sensitivity, in comparison with the sensitivity of each assay alone. The study of the selected panel of sera that yielded false-positive GM test results showed that almost two-thirds of them were invalidated by negative BG test results, as observed previously by Persat et al. for false-positive GM test results due to cross-reactivity with ␤-lactam antibiotics (30) . Therefore, combining the two assays can be proposed when an IA diagnosis is difficult to establish, provided that the results of the two tests are positive.
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